Saturday 17 October 2026
Export NNNN’s income statement to Excel — free account
Anbio Biotechnology
NNNN Healthcare Medical Instruments & Supplies
Anbio Biotechnology’s revenue for fiscal 2025 (year ended December 2025) was $8.6 million, up 5.64% from fiscal 2024.
3.29
0.01
−0.30%
Follow NNNN
| Older periods | Dec '23 | Dec '24 | Jun '25 | Dec '25 | |
|---|---|---|---|---|---|
Current Ratio |
+1 more quarter Free account |
15.86 | 10.71 | 211.14 | 344.45 |
Net Debt/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
— | — | — | 0.00 | |
Operating CF/Net income |
0.00 | 0.00 | — | 0.00 | |
Capex/Depreciation |
0.00 | 0.00 | — | 0.00 | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.00 | 0.00 | — | 0.00 | |
Cash per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Shareholders Equity per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow |
0.90 | 2.08 | — | (6.74) | |
Working Capital |
14.76 | 16.80 | 27.55 | 30.16 | |
Capital Expenditures |
0.00 | 0.00 | — | 0.00 | |
Net Current Asset Value |
14.76 | 16.80 | 27.55 | 30.16 | |
| Other line items | |||||
Quick Ratio |
11.65 | 7.41 | 130.78 | 177.19 | |
Operating CF per Share |
0.00 | 0.00 | — | 0.00 | |
Capex per Share |
0.00 | 0.00 | — | 0.00 | |
Average Assets |
— | — | — | 22.10 | |
Average Common Equity |
— | — | — | 21.35 | |
Capex to Sales |
0.00 | 0.00 | — | 0.00 |
Columns are period end dates